Synvisc OA Therapy Boosts Margins, Holds Promise For New Indications
This article was originally published in The Gray Sheet
Executive Summary
Genzyme's recent reacquisition of marketing rights to the Synvisc knee osteoarthritis treatment will help the firm realize a hefty gross margins increase in 2005
You may also be interested in...
Genzyme reacquires Synvisc rights
Genzyme will pay Wyeth $121 mil. up-front, plus up to $294 mil. in milestones by 2012 to buy back marketing rights to the hyaluronic acid-based knee osteoarthritis treatment for the U.S. and certain European countries. Genzyme, which already markets Synvisc in the UK, France, Canada and Australia, estimates worldwide Synvisc sales at $240 mil. for 2004. The firm plans to combine Wyeth's 105-person dedicated U.S. sales force with its own 36-person U.S. team marketing Synvisc and Carticel autologous cultured chondrocytes for knee cartilage repair, extending its orthopedic market reach. Synvisc currently controls 65% of the U.S. viscosupplementation market. A U.S. hip trial is under way. Approved in the U.S. for knees in August 1997, Synvisc developer Biomatrix was acquired by Genzyme's Biosurgery division in 2000 (1"The Gray Sheet" March 13, 2000, p. 16)...
Genzyme Bid For Impath Unit Reflects Efforts To Raise Oncology Profile
Genzyme will gain access to an expanded menu of cancer diagnostic tests and physician services if a pending $215 mil. cash bid for Impath's cancer testing unit proves successful
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.